Alzheimer's Disease Trial, Recruiting NCT05710549 Sponsor: Lucie Bréchet Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT05710549
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For younger and older adults without memory or thinking problems:

  • Adults aged 18 to 35 years old (younger adults) or aged 55 and older (older adults)
  • People who show no signs of cognitive (thinking or memory) impairment, based on a standard memory test called the MoCA
  • People who are willing and able to agree to take part after the study has been fully explained to them
  • People who are willing to follow all study requirements

For people with Mild Cognitive Impairment (MCI — early-stage memory problems):

  • Adults aged 55 and older
  • People who have been formally diagnosed with MCI by a doctor
  • People whose diagnosis will be reviewed and confirmed by the study's medical doctor
  • People who score 18 or above on a standard memory and thinking test called the MMSE (or 21 and above for mild Alzheimer's disease)
  • People who score 0.5 or above on a standard scale used to measure memory-related decline (called the CDR)
  • People who have a history of, or currently experience, difficulties with personal memories (remembering events from their own life)
  • People who have been on a stable, unchanged dose of memory-related medications — such as donepezil, rivastigmine, or memantine — for at least 6 weeks in a row
  • People who have completed at least up to Year 8 of schooling (or equivalent)
  • People who score above 18 on the MoCA test, to help confirm they are able to meaningfully agree to take part
  • People who are willing and able to follow all study requirements

Who may not be able to join:

For younger and older adults without memory or thinking problems:

  • People who score below 26 on the MoCA memory test, which may suggest some cognitive difficulty
  • People who have a major mental health condition, such as major depression, schizophrenia, or psychosis
  • People who are blind or have other physical difficulties that would prevent them from completing the study tasks
  • People who cannot have an MRI scan for any medical reason
  • People who have any metal in their brain, skull, or body — unless a doctor has confirmed it is safe to proceed (for example, an MRI-compatible joint replacement; standard dental fillings are generally not an issue)

For people with Mild Cognitive Impairment (MCI):

  • People under 55 years of age
  • People who currently have a major psychiatric diagnosis, such as schizophrenia, bipolar disorder, or major depressive disorder
  • People who have any other progressive or inherited neurological condition (such as Parkinson's disease or multiple sclerosis), or an acquired neurological condition (such as a stroke, brain injury, or brain tumour), in addition to MCI
  • People who have had a head injury that caused a prolonged loss of consciousness
  • People who currently experience poorly controlled headaches, including those regularly taking medication to prevent migraines
  • People who have had unexplained fainting episodes that may have been seizures
  • People who have a history of seizures or epilepsy, or who have a parent or sibling with epilepsy — unless a specialist neurologist has determined there was a single seizure with a harmless cause (such as a childhood fever)
  • People who have an unstable or poorly controlled medical condition that could become dangerous if a seizure were to occur (such as certain heart conditions or asthma)
  • People who have any factors that would make a brain stimulation procedure called tACS unsafe — including a seizure within the past two years, use of certain medications that affect the brain, or having certain implanted medical devices such as a deep brain stimulator, pacemaker, cochlear implant, or medication pump — or who have an active skin condition such as eczema on the scalp
  • People who cannot have an MRI scan or receive tACS brain stimulation for any medical reason
  • People who have any metal in their brain, skull, or body — unless a doctor has confirmed it is safe (dental fillings are generally not an issue)
  • People who have implanted devices such as a pacemaker, medication pump, nerve stimulator, TENS unit, or a brain fluid shunt — unless a doctor has confirmed it is safe to proceed

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Lucie Bréchet, PhD, University of Geneva (UNIGE)

Phone: +41 22 379 08 52

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Lucie Bréchet
Registry
ClinicalTrials.gov
Start date
25 April 2022
Est. completion
1 May 2027

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Spatiotemporal dynamic changes measured with electroencephalography (hdEEG); Cognitive Assessment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov